Warfarin: An inconvenient truth

Melina Gattellari*, John Worthington, Nicholas Zwar

*Corresponding author for this work

Research output: Contribution to journalEditorialResearch

6 Citations (Scopus)

Abstract

In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.
Original languageEnglish
Pages (from-to)5-7
Number of pages3
JournalStroke
Volume40
Issue number1
DOIs
Publication statusPublished - 1 Jan 2009
Externally publishedYes

Fingerprint Dive into the research topics of 'Warfarin: An inconvenient truth'. Together they form a unique fingerprint.

  • Cite this